Precise Engineering of a Se/Te Nanochaperone for Reinvigorating Cancer Radio-Immunotherapy

被引:25
|
作者
Chang, Yanzhou [1 ,2 ]
Huang, Jiarun [1 ]
Shi, Sujiang [1 ]
Xu, Ligeng [1 ]
Lin, Hao [2 ]
Chen, Tianfeng [1 ,2 ]
机构
[1] Jinan Univ, Coll Chem & Mat Sci, Dept Chem, Guangdong Prov Key Lab Funct Supramol Coordinat Ma, Guangzhou 510632, Peoples R China
[2] Guangdong Med Univ, Affiliated Hosp, Dept Orthoped, Zhanjiang 524001, Peoples R China
基金
中国博士后科学基金;
关键词
nano-heterojunctions; radio-immunotherapy; radiosensitization; selenium; tellurium; RADIATION-THERAPY; NANOPARTICLES; NANOPLATFORM; RADIOTHERAPY; SURFACTANTS; GENERATION; MORPHOLOGY; LIQUIDS; GROWTH;
D O I
10.1002/adma.202212178
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Facilely synthesized nanoradiosensitizers with well-controlled structure and multifunctionality are greatly desired to address the challenges of cancer radiotherapy. In this work, a universal method is developed for synthesizing chalcogen-based TeSe nano-heterojunctions (NHJs) with rod-, spindle-, or dumbbell-like morphologies by engineering the surfactant and added selenite. Interestingly, dumbbell-shaped TeSe NHJs (TeSe NDs) as chaperone exhibit better radio-sensitizing activities than the other two nanostructural shapes. Meanwhile, TeSe NDs can serve as cytotoxic chemodrugs that degrade to highly toxic metabolites in acidic environment and deplete GSH within tumor to facilitate radiotherapy. More importantly, the combination of TeSe NDs with radiotherapy significantly decreases regulatory T cells and M2-phenotype tumor-associated macrophage infiltrations within tumors to reshape the immunosuppressive microenvironment and induce robust T lymphocytes-mediated antitumor immunity, resulting in great abscopal effects on combating distant tumor progression. This study provides a universal method for preparing NHJ with well-controlled structure and developing nanoradiosensitizers to overcome the clinical challenges of cancer radiotherapy.
引用
收藏
页数:15
相关论文
共 44 条
  • [1] Emerging Trends for Radio-Immunotherapy in Rectal Cancer
    Corro, Claudia
    Dutoit, Valerie
    Koessler, Thibaud
    CANCERS, 2021, 13 (06) : 1 - 28
  • [2] Using triple radio-immunotherapy to overcome cancer immunotherapy resistance
    Zengfu Zhang
    Xiaodong Zhang
    Dawei Chen
    Cancer Biology & Medicine, 2023, (11) : 788 - 794
  • [3] Using triple radio-immunotherapy to overcome cancer immunotherapy resistance
    Zhang, Zengfu
    Zhang, Xiaodong
    Chen, Dawei
    CANCER BIOLOGY & MEDICINE, 2023, 20 (11) : 788 - 794
  • [5] NOVEL APPROACHES TO THE DEVELOPMENT OF RADIO-IMMUNOTHERAPY COMBINATIONS IN CANCER
    Illidge, T.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S168 - S169
  • [6] Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy
    Dong, Qingrong
    Xue, Tingyu
    Yan, Haili
    Liu, Fang
    Liu, Ruixue
    Zhang, Kun
    Chong, Yu
    Du, Jiangfeng
    Zhang, Hui
    JOURNAL OF NANOBIOTECHNOLOGY, 2023, 21 (01)
  • [7] Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy
    Qingrong Dong
    Tingyu Xue
    Haili Yan
    Fang Liu
    Ruixue Liu
    Kun Zhang
    Yu Chong
    Jiangfeng Du
    Hui Zhang
    Journal of Nanobiotechnology, 21
  • [8] Biomimetic liposome amplifying mitochondrial damage to potential cancer radio-immunotherapy
    Ping, Wei
    Tang, Han
    Dou, Haijing
    Zhu, Daoming
    Li, Xiang
    Zhang, Ni
    COLLOIDS AND SURFACES B-BIOINTERFACES, 2024, 242
  • [9] Targeting osseous metastases: Rationale and development of radio-immunotherapy for prostate cancer
    Morris M.J.
    Pandit-Taskar N.
    Divgi C.
    Larson S.
    Scher H.I.
    Current Oncology Reports, 2004, 6 (3) : 222 - 229
  • [10] PEGylated liposomal doxorubicin improves oral cancer response to radio-immunotherapy
    Devkota, Laxman
    Bhavane, Rohan
    Badachhape, Andrew
    Veeramachaneni, Ratna
    Menon, Renuka
    Bhandari, Prajwal
    Cortes, Sofia
    Da Costa, Fabio Henrique Brasil
    Ghaghada, Ketan
    Young, Simon
    Sikora, Andrew G.
    Annapragada, Ananth V.
    CANCER RESEARCH, 2023, 83 (07)